GLP1R and obesity due to melanocortin 4 receptor deficiency: Recently, a treatment strategy using a GLP-1-based multi-target drug has been reported to improve obesity and exhibit higher antidiabetic efficacy compared to GLP-1 receptor agonists alone [23].